0 CHECKOUT
Global Hormone Replacement Therapy Market 2015-2019 - Product Image

Global Hormone Replacement Therapy Market 2015-2019

  • ID: 3498685
  • November 2015
  • Region: Global
  • 69 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • ANI Pharmaceuticals
  • Eli Lilly
  • Hisamitsu Pharmaceutical
  • Merck
  • Mylan Laboratories
  • MORE

Global Hormone Replacement Therapy Market 2015-2019
Covering: An in-depth study of the global hormone replacement therapy market and segmentation by type of hormonal therapy (estrogen replacement therapy and growth hormone replacement therapy), by route of administration (oral, parenteral, and transdermal), and by geography (the Americas, EMEA, and APAC). The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market, including F. Hoffmann-La Roche, Merck Serono, Novartis, Novo Nordisk, and Pfizer.

An overview of the hormone replacement therapy market
Hormone replacement therapy involves the replacement of the hormones in the body whose levels have become low, in case of women nearing menopause or patient with growth hormone deficiency due to conditions such as dwarfism. At present, the combination of drugs are used to treat the conditions, which are known to have a better safety and efficacy parameter. Unmet medical needs is one of the major drivers influencing the growth of the market. Therefore, the need for new treatment options with better safety results to accommodate the current unmet need is huge.

In 2014, READ MORE >

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • ANI Pharmaceuticals
  • Eli Lilly
  • Hisamitsu Pharmaceutical
  • Merck
  • Mylan Laboratories
  • MORE

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 06: Market segmentation by type of hormonal therapy
Estrogen replacement therapy
Growth hormone replacement therapy

PART 07: Market segmentation by route of administration
Oral
Parenteral
Transdermal

PART 08: Global estrogen replacement therapy market
Market overview
Market size and forecast

PART 09: Global growth hormone replacement therapy market
Market overview
Market size and forecast

PART 10: Geographical segmentation
Hormone replacement therapy market in Americas
Hormone replacement therapy market in EMEA
Hormone replacement therapy market in APAC

PART 11: Market drivers
Unmet medical needs
Advances in technology
Reformulation of approved drugs
Lifestyle changes

PART 12: Impact of drivers

PART 13: Market challenges
High cost of therapy
Adverse effects
Storage issues
Weak pipeline

PART 14: Impact of drivers and challenges

PART 15: Market trends
Novel drug delivery mechanisms
Paradigm shift toward non-hormonal therapies
Mergers and acquisitions

PART 16: Vendor landscape
Competitive scenario
Key news
Mergers and acquisitions
Market share analysis 2014
Other prominent vendors

PART 17: Key vendor analysis
F. Hoffmann-La Roche
Merck Serono
Novartis
Novo Nordisk

PART 18: Appendix
List of abbreviation

PART 19: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global hormone replacement therapy market 2014-2019 ($ millions)
Exhibit 03: Five forces analysis
Exhibit 04: Global hormone replacement therapy market segmentation by type of hormonal therapy, 2014 (%)
Exhibit 05: Global hormone replacement therapy market segmentation by type of hormonal therapy 2014-2019 ($ millions)
Exhibit 06: Global hormone replacement therapy market by route of administration
Exhibit 07: Global estrogen replacement therapy market 2014-2019 ($ millions)
Exhibit 08: Global growth hormone replacement therapy market 2014-2019 ($ millions)
Exhibit 09: Global hormone replacement therapy market by geography, 2014
Exhibit 10: Global hormone replacement therapy market by key geographies, 2014-2019 ($ millions)
Exhibit 11: Hormone replacement therapy market in Americas 2014-2019 ($ millions)
Exhibit 12: Hormone replacement therapy market in EMEA 2014-2019 ($ millions)
Exhibit 13: Hormone replacement therapy market in APAC 2014-2019 ($ millions)
Exhibit 14: Impact of drivers
Exhibit 15: Impact of drivers and challenges
Exhibit 16: Global sales of Nutropin 2012-2014 ($ millions)
Exhibit 17: Key takeaways: F. Hoffmann-La Roche
Exhibit 18: Global sales of Saizen 2012-2014 ($ millions)
Exhibit 19: Global sales of Gonal-f 2012-2014 ($ millions)
Exhibit 20: Key takeaways: Merck Serono
Exhibit 21: Key takeaways: Novartis
Exhibit 22: Global sales of Norditropin 2012-2014 ($ millions)
Exhibit 23: Key takeaways: Novo Nordisk
Exhibit 24: Global sales of Genotropin 2012-2014 ($ millions)
Exhibit 25: Global sales of Premarin 2012-2014 ($ millions)
Exhibit 26: Global sales of Depo Provera 2012-2014 ($ millions)
Exhibit 27: Key takeaways: Pfizer
Exhibit 28: Merck Serono: Product segmentation 2014
Exhibit 29: Merck Serono: Geographical segmentation by revenue 2014
Exhibit 30: Business segmentation by revenue in percentage, 2014
Exhibit 31: Novo Nordisk: Business segmentation by revenue 2013 and 2014
Exhibit 32: Novo Nordisk: Geographical segmentation by revenue 2014
Exhibit 33: Novo Nordisk: R&D expenditure 2014

Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • ANI Pharmaceuticals
  • Eli Lilly
  • Hisamitsu Pharmaceutical
  • Merck
  • Mylan Laboratories
  • MORE

New Report Released: – Global Harmone Replacement Therapy Market 2015-2019

The author of the report recognizes the following companies as the key players in the Global Harmone Replacement Therapy Market: F. Hoffmann-La Roche, Merck Serono, Novartis, Novo Nordisk and Pfizer

Other Prominent Vendors in the market are: Abbott Laboratories, Amgen, ANI Pharmaceuticals, Bayer, Eli Lilly, Hisamitsu Pharmaceutical, Ipsen, Merck, Mylan Laboratories, Orion, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries, and TherapeuticsMD.

Commenting on the report, an analyst from the research team said: “the global hormone replacement therapy market is expected to witness some trends during the forecast period, which would be major influencers for market dynamics. One such trend is the paradigm shift toward non-hormonal therapies such as clonidine, venlafaxine, fluoxetine, and gabapentin to reduce symptoms of menopause, which is a paradigm shift from hormone-based therapies.”

According to the report, one of the important drivers in the global hormone replacement therapy market is significant current unmet needs in the market to encourage vendors to enter it. The current treatment options are incapable of meeting the market requirements due to their lower safety profiles, thereby leaving large unmet needs in this market. The requirement for new treatment options with better safety results is huge.

Further, the report states that one of the major challenges is the high cost of hormone replacement therapy, which hinders its acceptability among patients. Many patients do not have the required budget to invest in high-cost treatment options, and it can result in treatment withdrawal.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Note: Product cover images may vary from those shown
4 of 5

- F. Hoffmann-La Roche
- Merck Serono
- Novartis
- Novo Nordisk
- Pfizer
- Abbott Laboratories
- Amgen
- ANI Pharmaceuticals
- Bayer
- Eli Lilly
- Hisamitsu Pharmaceutical
- Ipsen
- Merck
- Mylan Laboratories
- Orion
- QuatRx Pharmaceuticals
- Teva Pharmaceutical Industries
- TherapeuticsMD.

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Actavis
  • Smith & Nephew PLC.
  • Bayer AG
  • Hologic Inc.
  • Abbott Laboratories Ltd.
  • Polpharma SA